CLINICAL TRIALS PROFILE FOR LENABASUM
✉ Email this page to a colleague
Clinical Trials for Lenabasum
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02465450 ↗ | Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis | Completed | Corbus Pharmaceuticals Inc. | Phase 2 | The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with cystic fibrosis (CF). |
| NCT02466243 ↗ | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine. |
| NCT02466243 ↗ | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis | Terminated | University of Pennsylvania | Phase 2 | The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Lenabasum
Condition Name
Clinical Trial Locations for Lenabasum
Trials by Country
Clinical Trial Progress for Lenabasum
Clinical Trial Phase
Clinical Trial Sponsors for Lenabasum
Sponsor Name
